Ming Chen

Journal Article Vaccines (Basel) · November 13, 2024 Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target thi ... Full text Link to item Cite

IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.

Journal Article J Exp Med · November 4, 2024 Acquisition of prostate cancer stem cells (PCSCs) manifested during androgen ablation therapy (ABT) contributes to castration-resistant prostate cancer (CRPC). However, little is known about the specific metabolites critically orchestrating this process. H ... Full text Link to item Cite

Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology.

Journal Article Precis Clin Med · September 2024 Featured Publication The delivery of lipid nanoparticle (LNP)-based mRNA therapeutics has captured the attention of the vaccine research community as an innovative and versatile tool for treating a variety of human malignancies. mRNA vaccines are now in the limelight as an alt ... Full text Open Access Link to item Cite

Tracking down metabolic vulnerabilities in CDK12-mutant prostate cancer.

Journal Article Clin Transl Discov · August 2024 Featured Publication Full text Open Access Link to item Cite

Heat shock factor 1 directly regulates transsulfuration pathway to promote prostate cancer proliferation and survival.

Journal Article Commun Biol · January 3, 2024 There are limited therapeutic options for patients with advanced prostate cancer (PCa). We previously found that heat shock factor 1 (HSF1) expression is increased in PCa and is an actionable target. In this manuscript, we identify that HSF1 regulates the ... Full text Open Access Link to item Cite

Nuclear PTEN Regulates Thymidylate Biosynthesis in Human Prostate Cancer Cell Lines.

Journal Article Metabolites · August 11, 2023 Featured Publication The phosphatase and tensin homologue deleted on chromosome 10 (PTEN) tumor suppressor governs a variety of biological processes, including metabolism, by acting on distinct molecular targets in different subcellular compartments. In the cytosol, inactive P ... Full text Open Access Link to item Cite

RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.

Journal Article J Clin Invest · May 15, 2023 Featured Publication Inactivation of the RB1 tumor suppressor gene is common in several types of therapy-resistant cancers, including metastatic castration-resistant prostate cancer, and predicts poor clinical outcomes. Effective therapeutic strategies against RB1-deficient ca ... Full text Open Access Link to item Cite

Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer.

Journal Article J Pathol · May 2023 Neuroendocrine (NE) cells comprise ~1% of epithelial cells in benign prostate and prostatic adenocarcinoma (PCa). However, they become enriched in hormonally treated and castration-resistant PCa (CRPC). In addition, close to 20% of hormonally treated tumor ... Full text Link to item Cite

Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling.

Journal Article Cell Commun Signal · September 18, 2019 BACKGROUND: Prostate cancer development involves various mechanisms, which are poorly understood but pointing to epithelial mesenchymal transition (EMT) as the key mechanism in progression to metastatic disease. ABI1, a member of WAVE complex and actin cyt ... Full text Open Access Link to item Cite

The expanded role of fatty acid metabolism in cancer: new aspects and targets.

Journal Article Precis Clin Med · September 2019 Featured Publication Cancer cells undergo metabolic reprogramming to support cell proliferation, growth, and dissemination. Alterations in lipid metabolism, and specifically the uptake and synthesis of fatty acids (FAs), comprise one well-documented aspect of this reprogrammin ... Full text Open Access Link to item Cite

Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis.

Journal Article Nat Commun · August 16, 2019 The Anaphase Promoting Complex (APC) coactivator Cdh1 drives proper cell cycle progression and is implicated in the suppression of tumorigenesis. However, it remains elusive how Cdh1 restrains cancer progression and how tumor cells escape the inhibition of ... Full text Open Access Link to item Cite

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.

Journal Article Cell Res · June 2019 Although targeted therapies have proven effective and even curative in human leukaemia, resistance often ensues. IDH enzymes are mutated in ~20% of human AML, with targeted therapies under clinical evaluation. We here characterize leukaemia evolution from ... Full text Open Access Link to item Cite

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.

Journal Article Science · May 17, 2019 Featured Publication Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a critical tumor suppressive phosphatase that is active in its dimer configuration at the plasma membrane. Polyubiquitination by the ub ... Full text Open Access Link to item Cite

Abi1 loss drives prostate tumorigenesis through activation of EMT and noncanonical WNT signaling.

Conference Journal of Clinical Oncology · March 1, 2019 280 Background: Prostate cancer is characterized by heterogeneity of mechanisms which are poorly understood but pointing to epithelial plasticity as the key mechanism in progression to metastatic disease. ABI1, a member of WAVE c ... Full text Cite

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.

Journal Article Dev Cell · February 11, 2019 Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report that SPOP suppresses stem cell tra ... Full text Open Access Link to item Cite

Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis.

Journal Article J Clin Invest · January 2, 2019 Featured Publication Recurrent broad-scale heterozygous deletions are frequently observed in human cancer. Here we tested the hypothesis that compound haploinsufficiency of neighboring genes at chromosome 8p promotes tumorigenesis. By targeting the mouse orthologs of human DOK ... Full text Open Access Link to item Cite

Loss of LDAH associated with prostate cancer and hearing loss.

Journal Article Hum Mol Genet · December 15, 2018 Great strides in gene discovery have been made using a multitude of methods to associate phenotypes with genetic variants, but there still remains a substantial gap between observed symptoms and identified genetic defects. Herein, we use the convergence of ... Full text Open Access Link to item Cite

The functions and regulation of the PTEN tumour suppressor: new modes and prospects.

Journal Article Nat Rev Mol Cell Biol · September 2018 Featured Publication PTEN is a potent tumour suppressor, and its loss of function is frequently observed in both heritable and sporadic cancers. PTEN has phosphatase-dependent and phosphatase-independent (scaffold) activities in the cell and governs a variety of biological pro ... Full text Link to item Cite

Molecular Genetics of APL

Chapter · April 25, 2018 This book provides a comprehensive overview on the clinical issues and biology of acute promyelocytic leukemia (APL) and on the molecular mechanisms of targeted therapy with ATRA and ATO. ... Link to item Cite

Preclinical and Coclinical Studies in Prostate Cancer.

Journal Article Cold Spring Harb Perspect Med · April 2, 2018 Featured Publication Men who develop metastatic castration-resistant prostate cancer (mCRPC) will invariably succumb to their disease. Thus there remains a pressing need for preclinical testing of new drugs and drug combinations for late-stage prostate cancer (PCa). Insights f ... Full text Open Access Link to item Cite

An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer.

Journal Article Nat Genet · February 2018 Featured Publication Lipids, either endogenously synthesized or exogenous, have been linked to human cancer. Here we found that PML is frequently co-deleted with PTEN in metastatic human prostate cancer (CaP). We demonstrated that conditional inactivation of Pml in the mouse p ... Full text Open Access Link to item Cite

Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms.

Journal Article Nat Med · February 2018 Multiple immune-cell types can infiltrate tumors and promote progression and metastasis through different mechanisms, including immunosuppression. How distinct genetic alterations in tumors affect the composition of the immune landscape is currently unclea ... Full text Link to item Cite

Deregulated PP1α phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism.

Journal Article Nat Commun · January 15, 2018 Featured Publication The mitogen-activated protein kinase (MAPK) pathway is frequently aberrantly activated in advanced cancers, including metastatic prostate cancer (CaP). However, activating mutations or gene rearrangements among MAPK signaling components, such as Ras and Ra ... Full text Open Access Link to item Cite

The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function.

Journal Article Cancer Discov · April 2017 BRAF drives tumorigenesis by coordinating the activation of the RAS/RAF/MEK/ERK oncogenic signaling cascade. However, upstream pathways governing BRAF kinase activity and protein stability remain undefined. Here, we report that in primary cells with active ... Full text Open Access Link to item Cite

Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.

Journal Article Am J Pathol · December 2016 Increased polyamine synthesis is known to play an important role in prostate cancer. We aimed to explore its functional significance in prostate tumor initiation and its link to androgen receptor (AR) signaling. For this purpose, we generated a new cell li ... Full text Open Access Link to item Cite

Endosome and INPP4B.

Journal Article Oncotarget · January 5, 2016 Full text Open Access Link to item Cite

In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes.

Journal Article Cancer Discov · July 2015 UNLABELLED: The phosphatases PTEN and INPP4B have been proposed to act as tumor suppressors by antagonizing PI3K-AKT signaling and are frequently dysregulated in human cancer. Although PTEN has been extensively studied, little is known about the underlying ... Full text Open Access Link to item Cite

Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.

Journal Article Cancer Discov · May 2015 UNLABELLED: The ETS family of transcription factors has been repeatedly implicated in tumorigenesis. In prostate cancer, ETS family members, such as ERG, ETV1, ETV4, and ETV5, are frequently overexpressed due to chromosomal translocations, but the molecula ... Full text Open Access Link to item Cite

Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.

Journal Article Cancer Discov · August 2014 UNLABELLED: Prostate cancer is the most prevalent cancer in males, and treatment options are limited for advanced forms of the disease. Loss of the PTEN and TP53 tumor suppressor genes is commonly observed in prostate cancer, whereas their compound loss is ... Full text Open Access Link to item Cite

Pills of PTEN? In and out for tumor suppression.

Journal Article Cell Res · October 2013 The tumor-suppressive activity of PTEN has always been attributed to its endogenous intracellular function. Recently two different groups have demonstrated that PTEN is secreted/exported into the extracellular environment for uptake by recipient cells, and ... Full text Open Access Link to item Cite

DOK2 inhibits EGFR-mutated lung adenocarcinoma.

Journal Article PLoS One · 2013 Somatic mutations in the EGFR proto-oncogene occur in ~15% of human lung adenocarcinomas and the importance of EGFR mutations for the initiation and maintenance of lung cancer is well established from mouse models and cancer therapy trials in human lung ca ... Full text Open Access Link to item Cite

Distinct function of estrogen receptor α in smooth muscle and fibroblast cells in prostate development.

Journal Article Mol Endocrinol · January 2013 Estrogen signaling, through estrogen receptor (ER)α, has been shown to cause hypertrophy in the prostate. Our recent report has shown that epithelial ERα knockout (KO) will not affect the normal prostate development or homeostasis. However, it remains uncl ... Full text Link to item Cite

Reduced prostate branching morphogenesis in stromal fibroblast, but not in epithelial, estrogen receptor α knockout mice.

Journal Article Asian J Androl · July 2012 Early studies suggested that estrogen receptor alpha (ERα) is involved in estrogen-mediated imprinting effects in prostate development. We recently reported a more complete ERα knockout (KO) mouse model via mating β-actin Cre transgenic mice with floxed ER ... Full text Open Access Link to item Cite

Loss of epithelial oestrogen receptor α inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models.

Journal Article J Pathol · January 2012 Squamous metaplasia (SQM) is a specific phenotype in response to oestrogen in the prostate and oestrogen receptor (ER) α is required to mediate this response. Previous studies utilizing tissue recombination with seminal vesicle (SV) mesenchyme and prostati ... Full text Open Access Link to item Cite

Designer monotransregulators provide a basis for a transcriptional therapy for de novo endocrine-resistant breast cancer.

Journal Article Mol Med · 2010 The main circulating estrogen hormone 17beta-estradiol (E2) contributes to the initiation and progression of breast cancer. Estrogen receptors (ERs), as transcription factors, mediate the effects of E2. Ablation of the circulating E2 and/or prevention of E ... Full text Link to item Cite

CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells.

Journal Article Carcinogenesis · May 2009 Human prostate cancer (PCa) and prostate epithelial cells predominantly express estrogen receptor (ER) beta, but not ERalpha. ERbeta might utilize various ER coregulators to mediate the E2-signaling pathway in PCa. Here, we identified coiled-coil domain co ... Full text Open Access Link to item Cite

RRR-alpha-vitamin E succinate potentiates the antitumor effect of calcitriol in prostate cancer without overt side effects.

Journal Article Clin Cancer Res · January 1, 2009 PURPOSE: To determine the antitumor efficacy of using calcitriol combined with RRR-alpha-vitamin E succinate (VES) on prostate cancer. EXPERIMENTAL DESIGN: The effects of VES or VES in combination with calcitriol on the calcitriol target genes were evaluat ... Full text Link to item Cite

Generation and characterization of a complete null estrogen receptor alpha mouse using Cre/LoxP technology.

Journal Article Mol Cell Biochem · January 2009 Conventional estrogen receptor alpha knockout (neo-ERalphaKO, neo-ERalpha(-/-)) mice contain a truncated and chimeric ERalpha fusion protein that retains 35% estrogen-dependent transactivation activity, and therefore the in vivo ERalpha function is difficu ... Full text Link to item Cite

Defects of prostate development and reproductive system in the estrogen receptor-alpha null male mice.

Journal Article Endocrinology · January 2009 The estrogen receptor-alpha knockout (ERalphaKO, ERalpha-/-) mice were generated via the Cre-loxP system by mating floxed ERalpha mice with beta-actin (ACTB)-Cre mice. The impact of ERalpha gene deletion in the male reproductive system was investigated. Th ... Full text Open Access Link to item Cite

ERAP75 functions as a coactivator to enhance estrogen receptor alpha transactivation in prostate stromal cells.

Journal Article Prostate · September 1, 2008 BACKGROUND: Estrogen receptor alpha (ER alpha) has been reported to be expressed and function in the prostate stromal cells, and numerous evidences indicated that the stromal ER alpha signal pathway plays critical roles in prostate development and cancer. ... Full text Link to item Cite

The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.

Journal Article Clin Cancer Res · April 1, 2007 PURPOSE: Insulin-like growth factor binding protein-3 (IGFBP-3) is a well-known antiproliferative and proapoptotic molecule in prostate cancer, suggesting that targeting IGFBP-3 might produce clinical benefits. In prostate cancer cells, RRR-alpha-vitamin E ... Full text Link to item Cite

Tocopherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway.

Journal Article Cancer Res · November 1, 2005 Epidemiologic studies suggested that vitamin E has a protective effect against prostate cancer. We showed here that tocopherol-associated protein (TAP), a vitamin E-binding protein, promoted vitamin E uptake and facilitated vitamin E antiproliferation effe ... Full text Open Access Link to item Cite

ROLES OF VITAMIN E IN PROSTATE AND PROSTATE CANCER

Chapter · March 2005 Full text Cite

Functions of estrogen receptor in prostate and prostate cancer

Chapter · 2005 Prostate cancer is the second leading cause of death in men and its progression is highly dependent on androgens and androgen receptors. ... Cite

Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery.

Journal Article Biochem Biophys Res Commun · January 10, 2003 Several epidemiological studies have demonstrated that vitamin E is a chemopreventative agent for prostate cancer. alpha-Tocopheryl succinate (VES), a derivative of vitamin E, effectively modulates prostate cancer cell growth. However, little is known abou ... Full text Link to item Cite